Cyteir Therapeutics Inc. (CYT)
NASDAQ: CYT
· Real-Time Price · USD
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 9:00 PM
Cyteir Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 834K | 934K | 1.03M | 726K | 400K | 200K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -834K | -934K | -1.03M | -726K | -400K | -200K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -38.25M | -44.84M | -47.46M | -48.17M | -49.98M | -49.97M | -49.05M | -42.26M | -35.78M | -29.07M | -22.27M |
Interest Income | 4.38M | 2.75M | 1.54M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -33.22M | -40.73M | -44.45M | -46.06M | -49.08M | -49.74M | -48.92M | -42.13M | -35.67M | -29M | -22.21M |
Net Income | -30.88M | -37.68M | -41.29M | -43.82M | -48.23M | -49.61M | -48.89M | -42.13M | -35.67M | -29M | -22.21M |
Selling & General & Admin | 13.39M | 14.38M | 13.61M | 13.55M | 14.57M | 14.63M | 13.62M | 11.3M | 9.16M | 6.44M | 4.89M |
Research & Development | 24.86M | 30.46M | 33.85M | 34.62M | 35.41M | 35.34M | 35.43M | 30.96M | 26.62M | 22.63M | 17.38M |
Other Expenses | 1.26M | 1.97M | 2.08M | 2.11M | 896K | 230K | 137K | 133K | 106K | 67K | 64K |
Operating Expenses | 38.25M | 44.84M | 47.46M | 48.17M | 49.98M | 49.97M | 49.05M | 42.26M | 35.78M | 29.07M | 22.27M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.25M | 44.84M | 47.46M | 48.17M | 49.98M | 49.97M | 49.05M | 42.26M | 35.78M | 29.07M | 22.27M |
Income Tax Expense | -2.33M | -3.04M | -3.15M | -2.24M | -849K | -135K | -29K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 36.03M | 35.74M | 35.59M | 35.38M | 35.33M | 35.28M | 35.24M | 35.14M | 35.06M | 34.76M | 34.47M |
Shares Outstanding (Diluted) | 36.03M | 35.74M | 35.59M | 35.38M | 35.33M | 35.28M | 35.24M | 35.14M | 35.06M | 34.76M | 34.47M |
EPS (Basic) | -0.87 | -1.06 | -1.16 | -1.24 | -1.37 | -1.41 | -1.39 | -1.2 | -1.08 | -0.96 | -0.83 |
EPS (Diluted) | -0.87 | -1.06 | -1.16 | -1.24 | -1.37 | -1.41 | -1.39 | -1.2 | -1.08 | -0.96 | -0.83 |
EBITDA | -37.87M | -44.39M | -46.95M | -47.5M | -49.48M | -49.52M | -48.66M | -41.92M | -35.34M | -28.65M | -21.88M |
EBIT | -23.61M | -30.19M | -32.81M | -46.95M | -38.12M | -38.11M | -37.19M | -30.4M | -35.78M | -29.07M | -22.27M |
Depreciation & Amortization | 995K | 1.05M | 1.12M | 668K | 638K | 593K | 535K | 479K | 434K | 416K | 387K |